Richard O. Jenkins

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 795 citations · Full text

Medicine, Oncology, Pharmacology +13

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logié, Jennifer S. McKay et al. · Molecular Cancer Therapeutics · 2007 · 389 citations

Medicine, Oncology, Pharmacology +17

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Helen Jenkins, Yuichi Sakurai, Akira Nishimura et al. · Alimentary Pharmacology & Therapeutics · 2015 · 307 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Yuuichi Sakurai, Akira Nishimura, Gale Kennedy et al. · Clinical and Translational Gastroenterology · 2015 · 190 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +11

Multivariate analysis of the effects of age, particle size and landfill depth on heavy metals pollution content of closed and active landfill precursors

Abdulganiyu Omobolaji Adelopo, Parvez I. Haris, Babajide I. Alo et al. · Waste Management · 2018 · 101 citations

Engineering, Environmental Engineering, Environmental Sciences +16